Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from INSM

3 Healthcare Stocks Showing Why the Sector Still Has Momentum

Oscar Health, Hinge Health, and Insmed post strong earnings and revenue growth in 2026, with analysts projecting further upside despite sector risks like Medicaid cuts and drug pricing pressure.

MarketBeat · Sep 28

Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus

Insmed (NASDAQ:INSM) Chair and CEO Will Lewis said the company remains confident in the launch trajectory of BRINSUPRI, despite investor concerns over discontinuation rates that followed the company’s latest update. Speaking at a Bank of America healthcare conference, Lewis said the company intended

MarketBeat · May 18

This ‘Strong Buy’ Stock Is Trading at New 20-Year Highs

Insmed (INSM) is a biopharmaceutical company with strong momentum. Shares are trading at new 20-year highs. INSM has surged 128% over the past year. Analysts expect robust revenue and earnings growth, but opinions are mixed, with some cautioning the stock is overvalued. Today’s Featured Stock Valued at $34.3 billion, Insmed...

Barchart · Oct 8, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Lung Disease-Focused Insmed 'Must-Own' Name For Investors

William Blair initiated coverage on Insmed Incorporated (NASDAQ:INSM), citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation.

Benzinga · Aug 20, 2025

This ‘Strong Buy’ Pharma Stock Is Surging to New Highs

Insmed (INSM) shows strong technical momentum, hitting a new 52-week high on Aug. 18. INSM has a 100% “Buy” opinion from Barchart with impressive recent gains. Revenue is projected to grow nearly 29% this year and 126% next year, with earnings growth expected to accelerate in 2026. Wall Street analysts...

Barchart · Aug 19, 2025

FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease

The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated’s (NASDAQ:INSM) Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older.

Benzinga · Aug 12, 2025

Russell Rebalance: 3 Stocks Ready to Move Higher

The Russell reconstitution is underway; here are three stocks that are garnering interest as stocks that could move up to the Russell 1000

MarketBeat · Jun 20, 2025

Read news from The Economist, FT, and more,
with one subscription

Insmed: Q1 Earnings Insights

Insmed (NASDAQ:INSM) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Benzinga · May 5, 2022

Insmed's Return On Capital Employed Insights

Insmed (NASDAQ:INSM) brought in sales totaling $56.12 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 0.23%, resulting in a loss of $112.98 million.

Benzinga · Feb 18, 2022

Insmed: Q4 Earnings Insights

Insmed (NASDAQ:INSM) reported its Q4 earnings results on Thursday, February 17, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Benzinga · Feb 17, 2022

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.